Melatonin
| Evidensnivå: L5 | Förutsagda indikationer: 0 st |
Innehållsförteckning
Melatonin: No Repurposing Predictions Available
One-Sentence Summary
Melatonin is an endogenous neurohormone best known for regulating circadian rhythms and sleep-wake cycles, widely used as a supplement for insomnia and jet lag in many countries. However, this Evidence Pack contains no TxGNN repurposing predictions, and no approved indications or market authorization records were found in Taiwan. A full repurposing evaluation cannot be completed until the missing data is collected.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No regulatory records found in Taiwan |
| Predicted New Indication | No predictions available |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — model prediction unavailable; no supporting studies |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The current Evidence Pack provides no TxGNN repurposing predictions, no approved indication records, no mechanism of action data, and no safety profile — the minimum information needed to conduct a meaningful repurposing evaluation is entirely absent.
To proceed, the following is needed:
- TxGNN predictions: Run the melatonin candidate through the TxGNN model to obtain disease–drug prediction scores and candidate indications
- Mechanism of action (MOA): Query DrugBank API (DB01065) to retrieve pharmacological targets and pathway data
- Original indication baseline: Confirm approved indications via TFDA package insert or international label (e.g., EMA/FDA) since Taiwan has no registered products
- Safety data: Parse TFDA package insert PDF for warnings, contraindications, and special population guidance
- Drug–drug interaction (DDI) profile: Expand DDI query scope (e.g., DrugBank DDI endpoint, Lexicomp) as the current query returned no results
Note: This report reflects the state of the Evidence Pack as of 2026-04-20. Melatonin is not classified as antineoplastic; no cytotoxicity section is required. All sections dependent on
predicted_indicationshave been omitted per reporting rules, as that array is empty.Ansvarsfriskrivning
Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning. Klinisk validering krävs före klinisk tillämpning.